Clinical trials: Adaptive Trial
Head and Neck Neoplasms
ROCOCO - Adaptive IMRT Versus IMPT in Head and Neck Cancer
Given the lack of evidence for the benefit of particle therapy in relevant cases, he investigators proposed an in silico trial to investigate the dosimetric effect of contour changes for OAR as well as tumor during chemoradiation…
- Trial name
- ROCOCO (NCT02908386)
- Where
- United States
- Sponsor
- Maastricht Radiation Oncology
Heart Failure, Cardiogenic Shock
REMAP ECMO - Beta Receptor Modulation Trial
In this phase 2, single center, randomized clinical pilot trial, investigators will study the effect of a strategy involving a reduction of beta receptor (BR) stimulation (by decreasing dobutamine dosages) and subsequent BR…
- Trial name
- NCT06522594
- Testing
- Esmolol
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Hypertension, Condition
Adaptive Cognitive Training on Cognitive Function in Elderly Hypertension Patients in the Community
Objective A growing body of evidence supports hypertension as a risk factor for cognitive decline. Hypertension is significantly associated with accelerated cognitive decline, poorer cognitive function, and mild cognitive…
- Conditions
- Hypertension, Condition, Aging
- Trial name
- NCT06512922
- Testing
- adaptive cognitive training
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University
Stroke, Acute Ischemic, Medium Vessel Occlusion
INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of IMP-ACT. Acute ischemic stroke (AIS) caused by intracranial arterial occlusion remains a major cause of disability and…
- Trial name
- IMP-ACT (NCT07906275)
- Testing
- Mechanical Endovascular Thrombectomy, Intravenous Thrombolysis, Tenecteplase/Alteplase- depending upon availability at each treating centre
- Where
- 4 sites in Canada
- Volunteers
- 800 people
- Sponsor
- University of Calgary
Community-acquired Pneumonia, Influenza, COVID-19
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients…
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
COVID-19
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
- Trial name
- NCT04690387
- Testing
- AV-COVID-19, GM-CSF
- Where
- Indonesia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
COVID-19
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780463
- Testing
- MP0420, Remdesivir
- Where
- 105 sites in United States, Denmark and 8 more
- Volunteers
- 485 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Long COVID, Post COVID-19 Condition
Effect of Hi-OxSR for the Treatment of Post COVID Condition
The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction.
- Conditions
- Long COVID, Post COVID-19 Condition, Post Acute Sequelae of COVID-19
- Trial name
- RECLAIM-HiOxSR (NCT06928506)
- Testing
- Hi-OxSR device, Hi-Ox device
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Fecal Incontinence
Adaptive Behaviors Among Women With Bowel Incontinence: The ABBI Trial
This study focuses on the validation of the Adaptation Index instrument as a measurement of adaptive behaviors used to reduce symptoms of FI and to describe the use of adaptive behaviors among women with FI.
- Trial name
- ABBI (NCT00729144)
- Where
- 8 sites in United States
- Volunteers
- 133 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Glioblastoma Multiforme, Adult, Glioblastoma, IDH-mutant
UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly
The usual standard of care for patients over 65 diagnosed with glioblastoma ("GBM") or Grade 4 astrocytoma, IDH-mutant is a 3-week course of radiotherapy, with concurrent and adjuvant temozolomide (TMZ).
- Trial name
- UNITED2 (NCT05565521)
- Testing
- Dose escalation + Reduced Margin Adaptive Radiotherapy
- Where
- Canada
- Volunteers
- 55 people
- Sponsor
- Sunnybrook Health Sciences Centre
Wounds and Injuries, Venous Thromboembolism
STAT-STatin and Aspirin in Trauma
This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial examining the efficacy of statins and aspirin in the reduction of acute lung injury and venous thromboembolism in patients with…
- Trial name
- STAT (NCT02901067)
- Testing
- Aspirin and Rosuvastatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Denver Health and Hospital Authority
COVID-19
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity.
- Trial name
- PLATCOV (NCT05041907)
- Testing
- Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
- Where
- 7 sites in Brazil, Laos and 3 more
- Volunteers
- 3,800 people
- Sponsor
- University of Oxford
Acute Respiratory Distress Syndrome
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome
Platform adaptive embedded trial for acute respiratory distress syndrome (PETARDS) is a randomized, embedded, multifactorial, adaptive platform trial for ARDS.
- Trial name
- PETARDS (NCT05658692)
- Testing
- protective ventilation, prone position ventilation, glucocorticoid therapy
- Where
- 11 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Respiratory Failure
Comparing High-flow Nasal Cannula Oxygen and Noninvasive Ventilation to Standard Oxygenation in Non-selected ICU Patients Admitted for Hypoxemic ARF
The goal of this clinical trial is to determine whether one of the two oxygenation or ventilation strategies (NIV and/or HFNO) is superior to standard oxygen to reduce 28-day mortality rate in hypoxemic acute respiratory failure…
- Trial name
- KISS (NCT05812911)
- Testing
- Standard oxygen, HFNO, NIV
- Where
- France
- Volunteers
- 1,470 people
- Sponsor
- University Hospital, Montpellier
COVID-19
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients.
- Trial name
- I-SPY_COVID (NCT04488081)
- Testing
- Remdesivir, Imatinib Mesylate, Dexamethasone
- Where
- 36 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Autism Spectrum Disorder, Major Depressive Disorder
rTMS for Depression in Young Adults With Autism
The current clinical trial is focused on evaluating the efficacy of rTMS for treatment of depression in youth and young adults (hereafter called transition aged youth, TAY) with autism spectrum disorder (ASD).
- Trial name
- rTMS-MDD (NCT04972136)
- Testing
- Active Bilateral Theta Burst Stimulation
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Sleep Apnea, Heart Failure
Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure
Sleep Apnea (SA) is a disorder that causes pauses in breathing during sleep that expose the heart to oxygen deprivation. It is common in patients with heart failure (HF) where it is associated with increased risk of…
- Trial name
- ADVENT-HF (NCT01128816)
- Testing
- Adaptive Servo Ventilation
- Where
- 49 sites in United States, Brazil and 7 more
- Volunteers
- 732 people
- Sponsor
- Toronto Rehabilitation Institute
Disabilities, Obesity and Overweight
Development of an Inclusive Adaptive Treatment Strategy for Weight Loss in People With Prediabetes Using a Sequential Multiple Assignment Randomized Trial
This is a sub-study to NCT04745572 to include a new cohort of participants with disabilities. This 16-week study will use an experimental approach called the Sequential Multiple Assignment Randomized Trial to help determine which…
- Conditions
- Disabilities, Obesity and Overweight, Prediabetes
- Trial name
- iADAPT (NCT06976307)
- Testing
- High Carbohydrate Diet, Reduced Carbohydrate Diet
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Alcohol Use Disorder, Injury Traumatic
PRACT to Investigate Controlling Alcohol Related Harms in a Low-Income Setting; Emergency Department BIs in Tanzania
Alcohol use is rapidly increasing in low- and middle-income countries, where it is inexpensive, readily available, poorly regulated, and there are few resources devoted to promoting safe alcohol use.
- Conditions
- Alcohol Use Disorder, Injury Traumatic, Trauma
- Trial name
- PRACT (NCT04535011)
- Testing
- PPKAY (brief intervention), Standard Booster, Personalized Booster
- Where
- Tanzania
- Volunteers
- 674 people
- Sponsor
- Duke University
Brain Neoplasms, Central Nervous System Neoplasms
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
The goal of Part I of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given with bevacizumab to patients with glioblastoma.
- Trial name
- NCT01582152
- Testing
- TPI287, Bevacizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center